Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'on LAG-3 Failure and Eylea Erosion Risk'
Tweet Send to a Friend
(Updated - May 18, 2026 1:08 PM EDT)
Leerink Partners analyst Andrew Berens downgraded Regeneron Pharma (NASDAQ: REGN) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst Andrew Berens downgraded Regeneron Pharma (NASDAQ: REGN) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
